| | Characteristic | Number of patients and % of those tested with variable |
| | Age (years) | 53.9 ± 11.5 | | Female sex, n (%) | 280 (53.9) | | Ethnicity: Black African, n (%)/other, n (%) | 515 (99.2)/4 (0.8) | | Cardiovascular disease, n (%) | 2 (0.4) | | Stroke/TIA, n (%) | 1 (0.2) | | Retinopathy, n (%) | 4 (0.8) | | Neuropathy, n (%) | 3 (0.6) | | Nephropathy, n (%) | 1 (0.2) | | HbA1c (%) | 9.1 ± 2.6 | | Systolic BP (mmHg) | 138 ± 18.4 | | Diastolic BP (mmHg) | 82 ± 10.3 | | TC (mmol/L) | 4.2 ± 1 | | TG (mmol/L) | 1.5 ± 0.9 | | LDL-C (mmol/L) | 2.4 ± 0.9 | | HDL-C (mmol/L) | 1.1 ± 0.3 | | Glycaemic control agents | | | Diet only, n (%) | 9 (1.7) | | 1 oral, no insulin, n (%) | 115 (22.2) | | ≥2 oral, no insulin, n (%) | 140 (27.0) | | Insulin only, n (%) | 47 (9.1) | | Combination—insulin with 1 oral, n (%) | 202 (38.9) | | Combination—insulin with ≥2 oral, n (%) | 6 (1.2) | | Biguanides, n (%) | 450 (86.7) | | Sulphonylureas, n (%) | 159 (30.6) | | Antihypertensive agents | | | Antihypertensive treatment, n (%) | 459 (88.4) | | Monotherapy, n (%) | 115 (25.1) | | Combination therapy (2 classes), n (%) | 121 (26.4) | | Combination therapy (3 classes), n (%) | 132 (28.8) | | Combination therapy (4 classes), n (%) | 67 (14.6) | | Combination therapy (≥5 classes), n (%) | 24 (5.2) | | ACE inhibitors, n (%) | 403 (87.8) | | Lipid-lowering agents | | | Statin treatment, n (%) | 133 (25.6) | | Other agents | | | Antiplatelet treatment, n (%) | 136 (26.2) | | Thyroid treatment, n (%) | 6 (1.2) |
|
|
